Future directions of pharmacotherapy of chronic obstructive pulmonary disease: the UPLIFT trial

tiotropium, anticholinergics, COPD, FEV1 decline, quality of life, mortality, exacerbations, adverse events

1. Jemal A., Ward E., Hao Y. et al. Trends in the leading causes of death in the United States, 1970–2002. J. A. M. A. 2005; 294: 1255–1259.

2. GOLD. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Update 2006. Available at: http://www.goldcopd.org/GuidelinesResources.asp?l1=2&l2=0.

3. Garcia-Ayremick J., Farrero E., Felez M.A. et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100–105.

4. Antonelli Incalzi R., Fuso L., De Rosa M. et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 2794–2800.

5. Suissa S., McGhan R., Niewoehner D., Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2007; 4 (7): 535–542.

6. Quassem A., Snow V., Shekelle P. et at. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American college of physicians. Ann. Inter. Med. 2007; 147 (9): 633–638.

7. Gartlehner G., Hansen R.A., Carsson S.S. et al. Efficacy and safety of inhaled corticosteroids in pateints with COPD: A systematic review and meta-analysis of health outcomes. Ann. Fam. Med. 2006; 4 (3): 253–262.

8. Wise R., Connett J., Weinmann G. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive lung disease. N. Engl. J. Med. 2000; 343: 1902–1909.

9. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340: 1948–1953.

10. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.

11. Vincken W., van Noord J.A., Greefborst A.P.M. et al. Improved helth outcomes in patiens COPD during 1 yr,s treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.

12. Anzuetto A., Tashkin D., Menjoge S. et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmac. Ther. 2005; 18: 75–81.

13. Tonnel A.B., Perz T., Grosbois J.M. et al. Improvement in HRQoL of COPD patients after 9 months′s treatment with tiotropium bromide: use of a new scale for daily medical practice. Eur. Respir. J. 2005; 26: 290s.

14. Cassaburi R., Mahler D.A., Jones P.W. et al. Long-term evalution of once-daily inhaled dosing with tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.

15. Dusser D., Bravo M.-L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27 (5): 1076.

16. Tashkin D.P., Celli B., Seen S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.

17. American Thoracic Society. Standartisation of spirometry; 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107–1136.

18. Tashkin D.P., Celli B., Decramer M. et al. Bronchodilator resposiveness in patients with COPD. Eur. Respir. J. 2008; 31: 742–750.

19. Celli B., Decramer M., Tashkin D. et al. Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups. In: Proceedings of the ATS Intern Conference. San Francisco; 2007. Abs. 849.

20. Tashkin D.P., Celli B., Decramer M. et al. Prescribing patterns according to COPD treatment guideline in patients enrolled in a global clinical trial. In: Proceedings of the ATS International Conference. San Diego; 2006. Abs. 274.

21. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332–338.

22. Decramer M., Celli B., Tashkin D. et al. Regional differences in the treatment of patients with moderate COPD in a global clinical trial. In: 16th Annual congress of ERS 2006. Munich; 2006.

23. Decramer M., Tashkin D.P., Celli B. et al. Predictors exacerbations of COPD in a large global clinical trial. In: Proceedings of the ATS International Conference. San Diego; 2006. Abs. 271.

24. Celli B., Decramer M., Tashkin D.P. et al. Predictors of mortality in a large global CPD clinical trial. In: Proceedings of the ATS International Conference. San Diego; 2006. Abs. 726.

25. Kesten S.F., Jara M., Wenrworth C., Lapes S. Pooled clinical trial analysis of the safety of the tiotropium. Chest 2006; 130: 1695–1703.